Acrivon Therapeutics (NASDAQ:ACRV) Stock Keeps “Market Outperform” Rating at Citizens Jmp

Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report)‘s stock had its “market outperform” rating reissued by Citizens Jmp in a report issued on Tuesday, Benzinga reports.

Several other equities analysts have also recently issued reports on the stock. Wall Street Zen cut shares of Acrivon Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 7th. Jefferies Financial Group restated a “buy” rating on shares of Acrivon Therapeutics in a research report on Wednesday, November 11th. Finally, Weiss Ratings raised Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 9th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.50.

Check Out Our Latest Research Report on Acrivon Therapeutics

Acrivon Therapeutics Price Performance

Shares of NASDAQ:ACRV opened at $1.46 on Tuesday. Acrivon Therapeutics has a 12 month low of $1.27 and a 12 month high of $3.56. The stock has a market cap of $62.56 million, a price-to-earnings ratio of -0.78 and a beta of 1.96. The stock’s 50 day moving average price is $1.82 and its 200 day moving average price is $1.74.

Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) last issued its quarterly earnings results on Monday, November 16th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. On average, sell-side analysts expect that Acrivon Therapeutics will post -1.71 EPS for the current year.

Insider Buying and Selling

In related news, CEO Peter Blume-Jensen sold 14,036 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $2.21, for a total transaction of $31,019.56. Following the completion of the sale, the chief executive officer directly owned 2,230,052 shares in the company, valued at approximately $4,928,414.92. This trade represents a 0.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 14,843 shares of company stock worth $32,549. Company insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On Acrivon Therapeutics

Several institutional investors have recently made changes to their positions in ACRV. StoneX Group Inc. acquired a new stake in shares of Acrivon Therapeutics in the 3rd quarter valued at $43,000. Spark Investment Management LLC acquired a new stake in Acrivon Therapeutics in the 2nd quarter worth approximately $50,000. Empowered Funds LLC acquired a new stake in Acrivon Therapeutics in the 3rd quarter worth approximately $117,000. Renaissance Technologies LLC lifted its holdings in Acrivon Therapeutics by 19.6% in the 1st quarter. Renaissance Technologies LLC now owns 758,440 shares of the company’s stock worth $1,054,000 after purchasing an additional 124,271 shares during the last quarter. Finally, Marshall Wace LLP boosted its position in Acrivon Therapeutics by 2.0% during the third quarter. Marshall Wace LLP now owns 542,344 shares of the company’s stock worth $1,112,000 after purchasing an additional 10,488 shares during the period. 71.62% of the stock is currently owned by institutional investors and hedge funds.

About Acrivon Therapeutics

(Get Free Report)

Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for cancer. Its research focuses on identifying treatments for patients whose tumors have molecular characteristics that may make them more likely to respond to a particular therapy. The company’s Acrivon Predictive Precision Proteomics (AP3) platform analyzes protein activity in tumor samples to identify these characteristics and help guide patient selection. Acrivon’s clinical-stage candidate ACR-368 is a small-molecule inhibitor of the CHK1 and CHK2 enzymes being studied in solid tumors.

Recommended Stories

Analyst Recommendations for Acrivon Therapeutics (NASDAQ:ACRV)

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.